STOCK TITAN

Palisade Bio (PALI) director Emil Chuang reports new RSU awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PALISADE BIO director Emil Chuang reported equity-based compensation and an RSU vesting. On June 10, 2026, he exercised restricted stock units (RSUs) into 20,200 shares of common stock and received an additional grant covering 592,300 shares, both at a stated price of $0.00 per share.

The RSU grants are subject to service-based vesting. One grant vests in three equal annual installments starting on the earlier of the 2027 annual meeting of stockholders or the anniversary of June 10, 2026, contingent on continued service. Another RSU grant vested in full on June 10, 2026.

Positive

  • None.

Negative

  • None.
Insider Chuang Emil
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 20,200 $0.00 --
Grant/Award Common Stock 592,300 $0.00 --
Exercise Common Stock 20,200 $0.00 --
Holdings After Transaction: Restricted Stock Units — 40,400 shares (Direct, null); Common Stock — 592,300 shares (Direct, null)
Footnotes (1)
  1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
Common shares from RSU exercise 20,200 shares Common Stock acquired via RSU exercise on June 10, 2026
Compensation-related equity grant 592,300 shares Common Stock reported as acquired on June 10, 2026 at $0.00
RSU position after transactions 40,400 RSUs Restricted Stock Units reported following derivative transaction
Common shares after RSU exercise 612,500 shares Total common stock reported following one June 10, 2026 transaction
Exercise price per RSU $0.00 per share Conversion or exercise price for 20,200 RSUs into common stock
RSU vesting schedule 3 equal annual installments Service-based vesting beginning around 2027 stockholder meeting or June 10, 2026 anniversary
Restricted Stock Units financial
"The Reporting Person was granted restricted stock units ("RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
service-based vesting requirement financial
"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments"
annual meeting of stockholders financial
"the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026"
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chuang Emil

(Last)(First)(Middle)
C/O PALISADE BIO, INC.
4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)
DENVER COLORADO 80237

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A(1)592,300A(1)592,300D
Common Stock06/10/2026M(2)20,200A(2)612,500D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(3)06/10/2026M20,200 (3) (3)Common Stock20,200$040,400D
Explanation of Responses:
1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.
2. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.
3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
/s/ Ryker Willie, Attorney-in-Fact for Emil Chuang06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PALISADE BIO (PALI) director Emil Chuang report?

Emil Chuang reported acquiring equity through compensation-related awards. On June 10, 2026, he received a grant linked to 592,300 shares of common stock and exercised restricted stock units into 20,200 common shares, all at a stated transaction price of $0.00 per share.

What type of securities did Emil Chuang acquire in the latest PALISADE BIO Form 4?

He acquired PALISADE BIO common stock and restricted stock units. One transaction converted 20,200 RSUs into common shares, while another granted equity tied to 592,300 shares. These awards reflect non-cash, compensation-related acquisitions rather than open-market stock purchases or sales.

How do the PALISADE BIO RSUs granted to Emil Chuang vest over time?

The RSUs are subject to service-based vesting. One grant vests in three equal annual installments, beginning on the earlier of the 2027 annual stockholder meeting or the anniversary of June 10, 2026, provided Emil Chuang maintains continuous service with PALISADE BIO through each vesting date.

Did Emil Chuang buy or sell PALISADE BIO (PALI) shares on the open market?

The reported transactions do not reflect open-market buying or selling. They show compensation-related RSU grants and an RSU conversion into 20,200 common shares, each recorded with a transaction price of $0.00 per share, indicating non-cash equity awards rather than market trades.

What does the June 10, 2026 RSU vesting mean for PALISADE BIO director ownership?

On June 10, 2026, an RSU grant vested and converted into 20,200 common shares for Emil Chuang. This increased his directly held common stock through equity compensation, aligning part of his compensation with PALISADE BIO’s share performance rather than cash salary.